GLP-1 side effects: what’s normal, what’s not, when to call

The mechanism that makes GLP-1 receptor agonists useful for weight management — slowed gastric emptying, increased satiety, central appetite suppression — is the same mechanism behind their most common side effects. That is worth stating directly, because it explains why the side effects are largely dose-related, why they tend to concentrate around the first one to two weeks after each step up, and why almost all of them improve with time on dose if you let them. Compounded GLP-1 is compounded under section 503A of the FD&C Act; compounded GLP-1 is NOT FDA-approved as a finished product, and the side-effect categories below apply to GLP-1 receptor agonist therapy in general.

What is normal: the common, dose-related list

The following side effects are the ones clinicians see most often. They are not signs that something has gone wrong. They are the body adjusting to slower gut motility and altered appetite signaling.

• Nausea. Most common. Usually peaks in the first 48 to 72 hours after an injection or after a dose step-up, and improves over the following week. Worst with large, fatty, or fast-eaten meals.
• Decreased appetite. Not a side effect per se — it is the intended pharmacology. The thing to watch is that you are still eating enough protein and drinking enough water.
• Constipation. Extremely common, often underreported because patients are embarrassed. Address it early with fiber and fluids; do not wait until you have been five days without a bowel movement.
• Diarrhea. Less common than constipation, but real. Sometimes alternating with constipation.
• Eructation (“sulfur burps”). The signature GLP-1 burp. Smells strongly of sulfur, usually appears after a heavier meal, and is more annoying than medically significant.
• Fatigue. Often nutritional, not pharmacologic. When patients eat less without paying attention to protein and electrolytes, energy drops.
• Injection-site reactions. Mild redness or itching at the injection site, lasting a day or two.
• Reflux. Slowed gastric emptying can worsen reflux symptoms in patients who are prone to them.

How to actually manage the common ones

For nausea

Eat smaller, more frequent meals. Lead with protein, then vegetables, then any starches. Cut back on fried foods, heavy cream sauces, and very large portions — not forever, just through the dose adjustment window. Ginger, peppermint tea, and cold or room-temperature foods often sit better than hot, aromatic ones. If nausea persists past a week at a given dose, your clinician may pause the next step-up or temporarily step down.

For constipation

Hydration first: most patients on GLP-1 are drinking less water than they think because thirst signaling is dulled by reduced overall intake. Target 2 to 3 liters of water daily for most adults, more in heat or with exercise. Add 25 to 35 grams of fiber per day from food when possible, or a soluble-fiber supplement. Magnesium citrate or magnesium oxide can be a useful short-term tool; discuss with your clinician before making it a daily habit.

For fatigue

Audit your intake honestly for 48 hours. Most fatigue on GLP-1 traces back to under eating: too few total calories, not enough protein, low sodium and potassium, or skipping meals because you are not hungry. The fix is rarely the medication. It is eating with intention rather than waiting for hunger that no longer arrives on time.

What is not normal: when to call your clinician today

Some symptoms are not a normal adjustment and should not be ridden out. Contact your clinician the same day — or in some cases go to an urgent care or emergency department — if you experience any of the following:

• Severe, persistent abdominal pain, particularly upper abdominal pain that radiates to the back. Pancreatitis is uncommon but serious.
• Right-upper-quadrant pain with fatty meals, fever, or jaundice. Possible gallbladder disease; rapid weight loss raises the risk.
• Vomiting that prevents you from keeping fluids down for more than 24 hours. Dehydration risk; also a sign the current dose is not tolerated.
• Signs of dehydration: dizziness on standing, dark urine, headache, cramping, racing heart.
• A neck mass or persistent hoarseness. Rare but a stop sign given the boxed warning.
• Severe allergic reaction: facial swelling, difficulty breathing, widespread hives — call 911.
• Symptoms of low blood sugar (shakiness, sweating, confusion), particularly if you are also taking insulin or a sulfonylurea.
• Vision changes in patients with type 2 diabetes — rapid glucose changes can transiently affect retinopathy.
• Mood changes or suicidal thoughts. These have been reported in post-marketing surveillance with GLP-1 therapy; if they appear, stop the medication and reach a clinician immediately.

The contraindication that does not move

Some patients should not be on GLP-1 therapy regardless of how tolerable it might otherwise be. This is the line that does not move:

Boxed warning: Risk of thyroid C-cell tumors. Do not use if you or a family member have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).

The honest framing

Most adults on GLP-1 therapy under appropriate supervision have a side-effect profile that is manageable, time-limited, and dose-related. A smaller group has a harder time and needs to slow titration, switch molecules, or step off entirely. The clinician–patient relationship is what makes that triage possible. If your platform’s answer to side effects is silence or a chat bot, you are not in a real care relationship. If the answer is a same-day conversation with a licensed clinician who can adjust the plan, you are. That is the real difference between a vial and a program.